Project Title
CENTRO PARA LA PREVENCIÓN Y EL CONTROL DEL CÁNCER (CECAN)
Partner Organisations
Pontificia Universidad Católica de Chile
Internal ID
152220002
Principal Investigator
BRUNO NERVI NATTERO
Type
basic research
Status
VIGENTE
Start Date
2022
End Date
2027
Investigators
JOHANNA PATRICIA ACEVEDO ROMO
18 results
Filters
Settings
Now showing 1 - 10 of 18
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE): A Randomized Trial Protocol(2024); Carolina Goic<jats:p>Cancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app’s impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients’ progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group’s EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990.</jats:p>2Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis(2024)Scopus© Citations 1 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The socioeconomic distribution of life expectancy and healthy life expectancy in Chile(2023)Scopus© Citations 1 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers(2024); Scopus© Citations 5 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The legal path for priority setting in Chile: a critical analysis to improve health planning and stewardship(Frontiers Media SA, 2024-01-08); 2Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol(2024); Carolina Goic<jats:p>Chemotherapy requires careful monitoring, but traditional follow-up approaches face significant challenges that were highlighted by the COVID-19 pandemic. Hence, exploration into telemonitoring as an alternative emerged. The objective is to assess the impact of a telemonitoring platform that provides clinical data to physicians overseeing solid tumor patients, aiming to enhance the care experience. The methodology outlines a parallel-group randomized clinical trial involving recently diagnosed patients with solid carcinomas preparing for curative intent chemotherapy. Eligible adult patients diagnosed with specific carcinoma types and proficient in Spanish, possessing smartphones, will be invited to participate. They will be randomized using concealed allocation sequences into two groups: one utilizing a specialized smartphone application called Contigo for monitoring chemotherapy toxicity symptoms and accessing educational content, while the other receives standard care. Primary outcome assessment involves patient experience during chemotherapy using a standardized questionnaire. Secondary outcomes include evaluating severe chemotherapy-associated toxicity, assessing quality of life, and determining user satisfaction with the application. The research will adhere to intention-to-treat principles. This study has been registered at ClinicalTrials.gov (NCT06077123).</jats:p>4Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Retrospective study on disparities in time-to-treatment by health insurance system in Chilean breast cancer patients(Medwave Estudios Limitada, 2025-04-10); 3Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Barriers to accessing formal cancer care from the perspective of informal caregivers: a qualitative study(Springer Science and Business Media LLC, 2025-04-21); ; ; 5Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Exploring the characteristics of cancer-centred civil society organisations in Chile: A qualitative study(Public Library of Science (PLoS), 2025-05-16); ; In Chile, civil society organisations in health have been historically active in population health and specifically in cancer; they have had an important role in addressing patients’ and families’ necessities. Although they occupy a central role, there is no clarity about who they are, how they are organised, the goals that guide their performance and how they materialize social participation in health. Based on that, this study aimed to explore the characteristics of civil society organisations that work in cancer in Chile and to identify the networks they build with other actors to achieve their goals. Materials and methods Qualitative case study using semi-structured online interviews with organisation representatives, politicians, decision-makers and academics related to cancer in Chile. Content analysis was performed, admitting emerging categories from the participants’ narratives.</jats:p> Results Three main profiles of organisations were identified: (i) Long-established organisations focused on influencing public policy and decision-making in cancer, (ii) Growing organisations focused on informing and supporting families and patients, (iii) Newly established organisations focused on patient well-being, such as sports activities. Relationships between groups and other actors involve perceived benefits like the growth of the organisations and funding for activities. However, perceived barriers and inequities are also identified, mainly lack of financial resources, competition between organisations and insufficient information. Discussion The objectives of civil society organisations in cancer are diverse and reflect multiple ways of practising social participation in health. Tensions generate unequal participation and missed opportunities to promote public health in cancer in Chile. The study highlights the importance of recognising cancer social organisations as essential actors in public health. It is crucial to involve them in formulating and implementing comprehensive responses to maximise the opportunities for progress in this field.4Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Challenges for gene therapy in the financial sustainability of health systems: a scoping review(2024); Manuel Antonio Espinoza<jats:title>Abstract</jats:title><jats:sec> <jats:title>Aim</jats:title> <jats:p>To review the available evidence about the strategies implemented or proposed for coverage or reimbursement for currently approved gene therapies.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>A scoping review was conducted to analyze the evidence published during the years 2016 to 2023. The main search criteria were coverage or reimbursement of gene therapy by healthcare systems. The eligible articles were those that described or proposed a financing model used to provide coverage in the various systems around the world.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The study identified 279 publications, and after removing duplicates and screening for eligibility, 10 were included in the study. The results show that various financing models have been proposed, including subscription-based payment models, outcome-based payment models, and amortization strategies. However, several barriers to implementing these models were identified, such as deficiencies in informatics systems for data collection, changes in laws or regulations, the lack of accessible clinical endpoints and administrative costs.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>This scoping review provides an overview of financing strategies for gene therapies. Gene therapies can cure rare or previously intractable diseases, but their high cost can make access difficult. Publishing experiences with these models can help evaluate their use and gather more evidence for their effectiveness.</jats:p> </jats:sec>1Scopus© Citations 16